These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Birkeland SA; Andersen HK; Hamilton-Dutoit SJ Transplantation; 1999 May; 67(9):1209-14. PubMed ID: 10342310 [TBL] [Abstract][Full Text] [Related]
9. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Clark G; Walsh G; Deshpande P; Koffman G Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256 [TBL] [Abstract][Full Text] [Related]
10. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center. Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320 [No Abstract] [Full Text] [Related]
11. Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients < or = 5 or > or = 55 years. MacDonell RC; Van Buren DH; Richie RE; Johnson HK; Nylander WA; Helderman JH; Ynares CM; Trusler LA; Green WF; Crowe DA Transplant Proc; 1994 Oct; 26(5):2518-21. PubMed ID: 7940774 [No Abstract] [Full Text] [Related]
12. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection. Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569 [TBL] [Abstract][Full Text] [Related]
13. Low incidence of acute rejection in kidney grafts treated with initial quadruple therapy: a retrospective analysis comparing two ATGs. Civati G; Minetti E; Busnach G; Perego A; Brando B; Broggi ML; Sansalone V; Forti D Transplant Proc; 1998 Jun; 30(4):1343-5. PubMed ID: 9636546 [No Abstract] [Full Text] [Related]
14. Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction. Nampoory MR; Abdulhalim M; Johny KV; Al-Jawad Donia FA; Nair MP; Said T; Homoud H; Samhan M; Al-Mousawi M Transplant Proc; 2002 Nov; 34(7):2916-9. PubMed ID: 12431656 [No Abstract] [Full Text] [Related]
15. Drug monitoring of mycophenolic acid in the early period after renal transplantation. Krumme B; Wollenberg K; Kirste G; Schollmeyer P Transplant Proc; 1998 Aug; 30(5):1773-4. PubMed ID: 9723276 [No Abstract] [Full Text] [Related]
16. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients. Lácha J; Símová M; Nosková L; Teplan V; Vítko S Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526 [No Abstract] [Full Text] [Related]
17. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice. Vathsala A; Lu YM Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348 [No Abstract] [Full Text] [Related]
18. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. Cronin DC; Bruce DS; Newell KA; Josephson MA; Millis JM; Piper JB; Ruebe M; Kirby M; Thistlethwaite JR; Woodle ES Transplant Proc; 1997; 29(1-2):307. PubMed ID: 9123010 [No Abstract] [Full Text] [Related]
19. Reduction in the incidence of early rejection in cadaveric renal allograft recipients treated with ATGAM induction and sequential mycophenolate mofetil. Florence LS; Howard DR; Chapman PH; Lieberman J; Perkinson DT; Marks WH Transplant Proc; 1997; 29(1-2):313-4. PubMed ID: 9123016 [No Abstract] [Full Text] [Related]